![]() ![]() Non-arteritic Ischemic Optic Neuropathy (NAION) blindness bone marrow derived stem cells (BMSC) optic neuropathy stem cells visual loss. Possible mechanisms by which visual improvement occurred may include BMSC paracrine secretion of proteins and hormones, transfer of mitochondria, release of messenger RNA or other compounds via exosomes or microvesicles and neuronal transdifferentiation of the stem cells. Stem cell therapy for neuropathy at Regenesis Stem Cell Center is an effective, low-risk, nonsurgical option that will help heal and prevent further nerve damage. Duration of visual loss did not appear to affect the ability of the eyes to respond to treatment. Charles Lee offers comprehensive stem cell treatment for neuropathy using state-of-the-art technology. ![]() Improvements typically manifested no later than 6 months post-procedure. The use of BMSC in the Stem Cell Ophthalmology Treatment Study achieved meaningful visual improvements in a significant percentage of the NAION patients reported. Improvements typically manifested no later than 6 months post procedure. The average LogMAR change in treated eyes was a gain of 0.364 (P=0.0089). There was an average of 3.53 Snellen lines of vision improvement per eye with an average 22.74% and maximum 83.3% improvement in LogMAR acuity per eye. The primary outcome was visual acuity as measured by Snellen or converted to LogMAR.įollowing therapy in SCOTS, 80% of patients experienced improvement in Snellen binocular vision (P=0.029) with 20% remaining stable 73.6% of eyes treated gained vision (P=0.019) and 15.9% remained stable in the post-operative period. Our stem cell treatments are experimental, but we only treat patients for whom we believe the risk/benefit ratio indicates treatment based on the state of the. Affected eyes were treated with either retrobulbar, subtenons and intravenous BMSC or, following vitrectomy, intra-optic nerve, subtenons and intravenous BMSC. The average duration of visual loss in eyes treated was 9.8 years and ranged from 1 to 35 years. The average age of the patients treated was 69.8 years. SCOTS is an Institutional Review Board approved clinical study utilizing autologous BMSC in the treatment of optic nerve and retinal diseases that meet inclusion criteria. Ten patients with bilateral visual loss due to sequential non-arteritic ischemic optic neuropathy (NAION) underwent autologous Bone Marrow Derived Stem Cell (BMSC) therapy within the Stem Cell Ophthalmology Treatment Study (SCOTS). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |